Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program

Area of Science:

• Pharmacometrics and Drug Development
• Regulatory Science
• Translational Medicine

Background:

• The Maximal Information-Based Drug Development (MIDD) Pilot Program has demonstrated benefits for drug companies.
• These benefits include improved decision-making, reduced development time, and cost savings.
• Qualitative benefits like enhanced understanding of MIDD strategies were also reported.

Purpose of the Study:

• To describe the collective experiences of industry participants in the MIDD Program.
• To provide insights into the process from meeting request to follow-up actions.
• To help future participants optimize their engagement with the MIDD Program.

Main Methods:

• Review of collective experiences from industry participants in the MIDD Program.
• Analysis of the entire process, including meeting requests and follow-up actions.
• Compilation of qualitative and quantitative benefits reported by sponsors.

Main Results:

• Participation in the MIDD Pilot Program led to substantial savings in development time and costs.
• Sponsors reported significant qualitative benefits, including new learnings and clearer MIDD strategies.
• The FDA has announced the continuation of the MIDD Paired Meeting Program under PDUFA VII, based on the program's success.

Conclusions:

• The MIDD Program offers tangible benefits for drug development, including efficiency gains and strategic clarity.
• Industry participants found value in the program's structured approach and regulatory interaction.
• The continuation of the MIDD Paired Meeting Program underscores its importance in modern drug development.